Chromobacterium violaceum

C. violaceum ferments glucose, trehalose, N-acetylglucosamine and gluconate but not L-arabinose, D-galactose, or D-maltose. It is positive for catalase and oxidase reactions. == Culture and identification ==

C. violaceum grows on readily on routine laboratory media. Most strains produce violacein, an ethanol soluble pigment, resulting in a distinct violet color. A PCR assay has been developed to identify C. violaceum. Care must be taken because Burkholderia pseudomallei is commonly misidentified as C. violaceum by many common identification methods. The two are readily distinguished because B. pseudomallei produces large wrinkled colonies, whereas C. violaceum produces a distinctive violet pigment. ==Medical significance==

C. violaceum rarely infects humans, but when it does it causes skin lesions, sepsis, and liver abscesses that may be fatal. The first reported case of Chromobacterium violaceum infection in humans in literature is from Malaysia in 1927. To date, cases have been reported from Argentina, Australia, Brazil, Canada, Cuba, India, Japan, Nigeria, Singapore, Sri Lanka, Taiwan, United States and Vietnam. The most common mode of entry of the bacteria into the body is through the injured skin coming in contact with soil or water containing the bacteria. The disease usually starts as a limited infection of the skin at the point of entry of the bacteria, which progresses to necrotizing metastatic lesions, then multiple abscesses of the liver, lung, spleen, skin, lymph nodes or brain, leading to severe septicaemia, culminating in multiorgan failure which may be fatal. Other reported pathologies include chronic granulomatosis, osteomyelitis, cellulitis, diarrhoea, septic spondylitis, conjunctivitis, periorbital and ocular infection. C. violaceum produces a number of natural antibiotics: • Aztreonam is a monobactam antibiotic that is active against gram-negative aerobic bacteria including Pseudomonas aeruginosa. It is marketed as Azactam. • Violacein is active against amoebae and trypanosomes; • Aerocyanidine is active against Gram-positive organisms; • Aerocavin is active against Gram-positive and Gram-negative organisms. It has been described as a cause of infection in gibbons. ==Treatment==

Human infection caused by C. violaceum is rather rare, therefore there are no clinical trials evaluating different treatments. Antibiotics that have been used to successfully treat C. violaceum include pefloxacin, Other antibiotics that appear to be effective in vitro include chloramphenicol and the tetracyclines. For theoretical reasons, infection would not be expected to respond to penicillins, cephalosporins, or aztreonam, although carbapenems like meropenem or imipenem may possibly work. Though the bacteria is reported to be resistant to first and second generation cephalosporins, susceptibility to newer cephalosporins is variable. ==Genome==

The complete genome was sequenced and the results were published in 2003. C. violaceum type strain ATCC 12472 was found to have 4,751,080 base pairs with a G + C content of 64.83% and 4,431 ORFs. ==References==